All News

Advanced prostate cancer patients who are treated with oral sodium clodronate appear to have improved survival rates, according to results of a British study.

The FDA Advisory Committee for Reproductive Health Drugs (ACRHD) has recommended approval of denosumab (Prolia) for prevention and treatment of bone loss in certain prostate cancer patients.

Financial solvency obstacles and implementing an electronic health record are the top challenges facing medical practices and their respective practice managers, according to a survey by the Medical Group Management Association (MGMA).

James L. Mohler, MD, has been promoted to senior vice president for translational research at Roswell Park Cancer Institute (RPCI) in Buffalo, NY.

Endoscopic technology developer Karl Storz Endoscopy-America, Inc. has established a reseller agreement with Rivulet Communications, which produces high-definition medical video technology for hospital IP networks.

Internationally recognized kidney disease expert Gregory G. Germino, MD, has been named deputy director of the National Institute of Health's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

A second and final phase III, multicenter, double-blind, placebo-controlled study of PSD502 for premature ejaculation treatment has met all endpoints, according to Sciele Pharma and Plethora Solutions Holdings. Those endpoints include intra-vaginal ejaculation latency time and the index of premature ejaculation (IPE; ejaculatory control, sexual satisfaction, and distress domains).

Researchers at the Stanford University School of Medicine, Stanford, CA have identified the first human bladder cancer stem cell and have explained its role in evading the body?s natural defenses.

Genentech, Inc. has earned FDA approval for bevacizumab (Avastin) plus interferon-alfa for treatment of metastatic renal cell carcinoma. Bevacizumab blocks the vascular endothelial growth factor (VEGF) protein responsible for tumor growth.

In the 15 years following a radical prostatectomy, there is only a 12% mortality rate directly connected to prostate cancer, regardless of the cancer?s aggressiveness, according to a multicenter study appearing in the Journal of Clinical Oncology online. Comparatively, there was a 38% rate of non-cancer-related death in this same group of patients.

Incidentally detected small renal masses (SRMs) are not always cancer, and even those that are biopsy-proven renal cell carcinoma tend to grow slowly initially and have a low risk of metastasis, according to analyses of data.

Among surgeons contemplating performing a minimally invasive partial nephrectomy, the choice of procedure boils down to the approach that provides the highest level of comfort for the surgeon.

It's not clear yet whether transvaginal mesh offers superior anatomic or symptomatic outcomes compared to traditional apical suspension repairs.

In patients with primary T1G3 bladder cancer who undergo initial treatment with endovesical bacillus Calmette-Guerin (BCG [TheraCys, TICE BCG]), development of high-grade disease recurrence after 3 months is a prognostic factor for progression.

New products from Uvision, Caldera Medical, Serono, Lumenis, American Medical Systems, and more.

While some urology practices are adding physician extenders, others are having as much difficulty finding them as finding urologists.

Urologists around the country lament the difficulty in finding and keeping good employees, and even gripe about the deteriorating performance and attitudes found in some of the more demanding positions. My advice: They're your employees, so it's time to take ownership of the problem.

Combination of an immunofluorescence test and cytology may improve quality of bladder cancer diagnostics.

In an earlier article, we examined the reasons why an early EMR adopter might need to migrate to an entirely new clinical information system and some of the important issues that need to be addressed in managing that migration. In this article, we show how one practice overcame these challenges.

The question is no longer if health care reform will occur, but when and what it will look like.

A non-bone-anchored male sling appears to resolve mild to moderate post-prostatectomy incontinence in up to 80% of patients and may also lead to significant improvement in erectile and sexual function.

A solitary positive apical margin following radical prostatectomy is associated with a higher biochemical recurrence rate than are negative surgical margins., but positive apical margins are associated with a lower recurrence rate than non-apical or multifocal positive margins are.

"We're just starting, but I'm not looking forward to it."

A study by psychologists and urologists has found that factors affecting erectile function after prostatectomy have much the same impact after other prostate cancer treatments.

Most women who undergo sacral neuromodulation for refractory overactive bladder report concomitant bowel symptoms when asked.

AUA has addressed a number of questions and controversies concerning small renal masses in a new clinical guideline reflecting current research. Steven C. Campbell, MD, PhD, guideline co-chair, discusses the rationale for the guideline and key recommendations.

Planned radical prostatectomy within 8 weeks of preoperative radiotherapy is well tolerated and may result in downstaging of the disease, according to results of a phase I study.